Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IRWD vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRWD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

IRWD Overall Winner 6-Pillar Tally: IRWD 5 – 1 TLPH Matrix Metrics: IRWD 6 – 4 TLPH

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 34.8/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -1474700.0% operating margin) and revenue trajectory (+9.0% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although IRWD compares more favorably head-to-head, both IRWD (34.8/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IRWD vs TLPH
IRWD NASDAQ Head-to-Head Winner
Ironwood Pharmaceuticals, Inc. - Class A
Pharmaceutical Preparations
$4.86
+0.62% 1D
Market Cap $802.9M
TTM Revenue $400M
Forward P/E 12.3x
Beta / 30D Vol 1.37β · 54% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 50.0 Fund 33.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 76
RSI-14: 75.5 · SMA20: $4.00 · SMA50: $3.98
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (IRWD 5 – 1 TLPH)

Columns: Metric · IRWD · TLPH
1. Valuation Multiples TLPH
Forward P/E 12.3x 1.0x
Trailing P/E 5.4x 1.0x
PEG Ratio N/M N/M
EV / Revenue 2.6x N/M
2. Growth & Scale IRWD
Revenue Growth (YoY) +9.0% +0.0%
Earnings Growth (YoY) +57.0% +0.0%
TTM Revenue (USD) $400M $1,000
Market Cap $802.9M $53.7M
3. Profitability & Quality IRWD
Gross Margin 76.4% N/A
Operating Margin 62.9% -1474700.0%
Net Profit Margin 37.4% 0.0%
Return on Equity (ROE) -574.7% -143.4%
4. Balance Sheet & Cash Flow IRWD
Cash Generation (TTM) $205M -$15M EBITDA
Cash Flow Margin 51.3% N/A
Net Cash / Leverage $250M Net Debt $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IRWD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 63.1% (6th %ile) 118.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IRWD
OpEx & R&D Intensity 13.5% of Rev ($54M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IRWD (6) vs TLPH (4)
Institutional Metric IRWD TLPH Criterion Row Edge
Market Capitalization
Scale
$802.9M $53.7M Larger Scale IRWD
Trailing P/E Ratio
Valuation
5.4x 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
12.3x 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+9.0% +0.0% Higher Growth IRWD
Operating Margin (TTM)
Profitability
62.9% -1474700.0% Higher Margin IRWD
Net Profit Margin
Profitability
37.4% 0.0% Higher Margin IRWD
Return on Equity (ROE)
Capital Efficiency
-574.7% -143.4% Higher ROE TLPH
52-Week Range Position
Momentum
68% ($3–$6) 20% ($1–$2) Stronger Trend IRWD
Beta / 30D Volatility
Risk Regime
1.37β · 54% Vol 1.11β · 58% Vol Lower Realized Risk IRWD
Unified Institutional Score
Composite Signal
34.8 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite TLPH
Trailing 12M Revenue (USD)
Operating Scale
$400M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
76.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$205M ($250M Net Debt) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRWD +59.15 pp
IRWD: +38.86% · TLPH: -20.29%
3M Horizon IRWD +41.61 pp
IRWD: +12.76% · TLPH: -28.85%
6M Horizon IRWD +30.88 pp
IRWD: +38.86% · TLPH: +7.98%
1Y Horizon IRWD +62.22 pp
IRWD: +44.21% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IRWD vs TLPH. Trailing 12-month operating profitability (IRWD 62.9% vs TLPH -1474700.0%) and valuation multiples (IRWD 12.3x vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

IRWD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$400M
Gross Margin76.4%
Op. Margin62.9%
ROE / Fwd P/E-574.7% · 12.3x
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IRWD CONSOLIDATION
134d in phase · OBV ACCUMULATION
Current IV 63.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IRWD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IRWD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $802.9M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($54M)
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IRWD vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 34.8/100 (SELL) at $4.86 (12.3x Forward P/E, 62.9% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Composite vs. Pillar Nuance: While TLPH currently prints a higher short-term Unified Composite Score (37.1/100 SELL vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -1474700.0% operating margin) and revenue trajectory (+9.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although IRWD compares more favorably head-to-head, both IRWD (34.8/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRWD leads the Growth & Scale pillar: IRWD posts +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, IRWD generates $400M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, IRWD deploys 13.5% of Rev ($54M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. IRWD trades at 12.3x Forward P/E, 5.4x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRWD (-574.7% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, IRWD carries 63.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.37β · 54% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.